Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...
GlobalData on MSN
Autolus doses first participant in obe-cel trial for progressive MS
The Phase I trial aims to recruit 18 adult participants to assess the efficacy, safety, and tolerability of obe-cel.
Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...
With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...
MedPage Today on MSN
Double-Action Lupus Drug Looks Good in Phase III Trial
A novel drug for systemic lupus erythematosus (SLE) first developed in China, and approved there since 2021, did well enough in a new placebo-controlled phase III trial that approval in Western ...
Covers low tumor burden “watch-and-wait” setting, an unmet medical needRegistrational Phase 3 watch-and-wait to start in 2026EO2463 has broad ...
Infectious bursal disease (IBD) is an immunosuppressive poultry disease. Reported globally, it can infect young broilers from ...
The global chronic lymphocytic leukemia therapeutics market is poised for steady expansion, with an expected compound annual growth rate (CAGR) of 7% from 2025 to 2030. Growth is driven by rapid ...
NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 ...
A breakthrough study reveals a new antibody that could transform the fight against HIV, neutralising over 98 percent of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback